Centaurus Financial Inc. boosted its position in Chemed Co. (NYSE:CHE - Free Report) by 136.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,071 shares of the company's stock after acquiring an additional 2,924 shares during the period. Centaurus Financial Inc.'s holdings in Chemed were worth $3,048,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Chemed by 34.4% during the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company's stock worth $47,000 after purchasing an additional 22 shares in the last quarter. American National Bank & Trust bought a new stake in Chemed during the third quarter worth $61,000. Mather Group LLC. raised its position in Chemed by 60.5% in the 2nd quarter. Mather Group LLC. now owns 183 shares of the company's stock valued at $99,000 after buying an additional 69 shares during the last quarter. Quarry LP lifted its stake in Chemed by 721.7% during the 2nd quarter. Quarry LP now owns 189 shares of the company's stock valued at $103,000 after acquiring an additional 166 shares in the last quarter. Finally, LRI Investments LLC purchased a new position in Chemed during the 1st quarter worth $171,000. 95.85% of the stock is owned by institutional investors and hedge funds.
Chemed Price Performance
Shares of CHE traded up $7.68 during midday trading on Friday, hitting $570.96. 113,335 shares of the company traded hands, compared to its average volume of 111,730. The stock has a 50-day moving average of $579.08 and a 200-day moving average of $565.00. Chemed Co. has a one year low of $523.33 and a one year high of $654.62. The firm has a market cap of $8.59 billion, a P/E ratio of 28.85, a PEG ratio of 2.39 and a beta of 0.46.
Chemed (NYSE:CHE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.76 by ($0.12). The firm had revenue of $606.18 million during the quarter, compared to analysts' expectations of $612.22 million. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.32 earnings per share. Sell-side analysts forecast that Chemed Co. will post 21.43 EPS for the current fiscal year.
Chemed Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Monday, November 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.35%. The ex-dividend date is Monday, November 18th. Chemed's payout ratio is 10.11%.
Insiders Place Their Bets
In related news, EVP Nicholas Michael Westfall sold 1,713 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $569.35, for a total value of $975,296.55. Following the transaction, the executive vice president now owns 6,109 shares of the company's stock, valued at $3,478,159.15. This represents a 21.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George J. Walsh III sold 400 shares of Chemed stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the sale, the director now directly owns 3,046 shares of the company's stock, valued at approximately $1,819,893.62. This trade represents a 11.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,113 shares of company stock worth $2,411,905 in the last ninety days. 3.32% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on CHE. StockNews.com downgraded shares of Chemed from a "buy" rating to a "hold" rating in a research report on Friday. Royal Bank of Canada decreased their price objective on Chemed from $697.00 to $633.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th.
Get Our Latest Stock Analysis on Chemed
About Chemed
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
